Efficacy of facial chemical peeling with salicylic acid and role of 4% hydroquinone as an adjuvant treatment modality in melasma

Journal of Pakistan Association of Dermatologists

Volumn 12, Issue OCT./DEC., 2002, Pages 183-189

  Bari, Arfan Ul ^a  

^a MILITARY HOSPITAL   (Pakistan)

Author keywords

Chemical peeling; Hydroquinone; Melasma; Salicylic acid

Indexed keywords

ACICLOVIR; BETAMETHASONE VALERATE; GLYCOLIC ACID; HYDROQUINONE; PHENOL; PYRUVIC ACID; RESORCINOL; SALICYLIC ACID DERIVATIVE; SUNSCREEN; TRICHLOROACETIC ACID;

ADJUVANT THERAPY; ADULT; ARTICLE; BURNING SENSATION; CELL TYPE; CHEMICAL PEELING; CHLOASMA; CLINICAL ARTICLE; CLINICAL OBSERVATION; DISEASE DURATION; DRUG EFFICACY; ERYTHEMA; EVALUATION; FEMALE; FITZPATRIK SKIN TYPE 4; FITZPATRIK SKIN TYPE 5; HERPES LABIALIS; HUMAN; HYPERPIGMENTATION; MALE; PAIN; RANDOMIZATION; SIDE EFFECT; SKIN ABRASION; SKIN ALLERGY; SKIN CRUSTING; SKIN DISEASE; SKIN IRRITATION; SKIN PIGMENTATION; STINGING SENSATION; SUN EXPOSURE; XEROSIS;

EID: 0042384497     PISSN: 15609014     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Grimes PE Melasma: Aetiologic and therapeutic considerations. Arch. Dermatol. 1995; 131: 1453-1457.
2. Griffiths CEM, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) improves melasma. A vehicle controlled clinical trial. Br. J. Dermatol 1993; 129: 415-421.
3. Sanches NP, Pathak MA, Sato S, Fitzpatric TB, Sanches TL, Mihrn MC Jr. Melasma: a clinical, light microscopic, ultrastructural and immunofluoresence study. J. Am. Acad. Dermatol. 1981; 4:689-710.
4. th ed. New York; Mc Graw-Hill, Inc, 1999: 940.
5. Green CKK, Griffith CEM, Finkel LJ, Hamilton TA, Ransby SMB, Ellis CN, Voorhees JJ. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle controlled clinical trial. Arch. Dermatol, 1994; 130:727-733.
6. Cotelessa C, Peris K, Onorati MT, Fargnoli MC, Chimenti S. The use of chemical agents in the treatment of different cutaneous hyperpigmentations. Dermatol surg, 1999; 25:6:450-454.
7. FDA/CFSAN: Office of cosmetic fact sheet. March 7, 2000.
8. Imayama S, Ueda S, Isoda M. Histologic changes in the skin of hairless mice following peeling with salicylic acid. Arch Dermatol 2000 Nov; 136(11): 1390-5.
9. Luis MB, Klaus G. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int. J. Dermatol. 1991; 30(12): 893-895.
10. Kligman D, Kligman AM: Salicylic acid peels for the treatment of photoaging. Dermatol Surg, 1998; 24:325-8.
11. Isoda M, Ueda S, Imayama S, Tsukahara K. New formulation of chemical peeling agent: histological evaluation in sun damaged skin model in hairless mice. J Dermatol Sci 2001Aug; 27 Suppl 1: S60-7.
12. Pi rard GE, Klighman AM, Stoudemayer T, L veque JL. Comparative effects of retinoic acid, glycolic acid and a lipophilic derivative of salicylic acid on photodamaged epidermis. Dermatology. 1999; 199(1);50-3.
13. Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol. Surg. 1999;25(1): 18-22.
14. Ueda S, Mitsugi K, Ichige K, Sakuma T, Ninomiya S, Sudou T. New formulation of chemical peeling agent: 30% salicylic acid in polyethylene glycol. Absorption and distribution of 14C-salicylic acid in polyethylene glycol applied topically, to skin of hairless mice. J Dermatol Sci 2002 Apr;28(3):211-8.
15. Sanchez IL, Vazquez M. A hydroquinone solution in the treatment of melasma. Int J Dermatol. 1982; 21: 55-58.
16. Glenn M, Grimes PE, Pitt E, Challet M, Kelley AP. Evaluation of clinical and light microscopic effects of various concentrations of hydroquinone. Clin Res. 1991; 39: 83A.
17. Snider RL, Theirs BH, Exogenous ochoronosis. J. Am Acad Dermatol. 1993; 28: 662-664.
18. David M, Duffy MD. Alpha hydroxy acids Trichloroacetic acids, risk/benefit strategies. J Dermatol Surg. 1998; 24: 181-189. Bari AU.
19. Effects of 4% hyroquinone as an adjuvant treatment to superficial chemical facial peeling with glycolic acid in melasma. J Pakistan Assoc Dermatol. 2002 Mar; 12(1):15-23.